Vir Biotechnology, Inc. (VIR)

NASDAQ: VIR · IEX Real-Time Price · USD
22.86
+0.14 (0.59%)
Mar 30, 2023, 2:22 PM EDT - Market open
0.59%
Market Cap 3.05B
Revenue (ttm) 1.62B
Net Income (ttm) 515.84M
Shares Out 133.53M
EPS (ttm) 3.83
PE Ratio 5.93
Forward PE 4.36
Dividend n/a
Ex-Dividend Date n/a
Volume 434,135
Open 22.77
Previous Close 22.72
Day's Range 22.60 - 23.01
52-Week Range 18.05 - 31.78
Beta 0.26
Analysts Buy
Price Target 51.15 (+123.8%)
Earnings Date May 4, 2023

About VIR

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of He... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2019
Employees 444
Stock Exchange NASDAQ
Ticker Symbol VIR
Full Company Profile

Financial Performance

In 2022, VIR's revenue was $1.62 billion, an increase of 47.51% compared to the previous year's $1.10 billion. Earnings were $515.84 million, a decrease of -2.41%.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for VIR stock is "Buy." The 12-month stock price forecast is $51.15, which is an increase of 123.80% from the latest price.

Price Target
$51.15
(123.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Is the Options Market Predicting a Spike in Vir Biotechnology (VIR) Stock?

Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.

1 day ago - Zacks Investment Research

SVB fall casts shadow on early-stage U.S. biotech

The collapse of Silicon Valley Bank will leave early-stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly-traded drug companies should escape ...

Other symbols: SIVBAXSMRYTM
2 weeks ago - Reuters

Vir Biotechnology to Participate in the Barclays Global Healthcare Conference

SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of...

3 weeks ago - GlobeNewsWire

The Top 7 Growth Stocks in Biotech

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

3 weeks ago - InvestorPlace

Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will parti...

1 month ago - GlobeNewsWire

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Misses Revenue Estimates

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -1,800% and 80.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st...

1 month ago - Zacks Investment Research

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact –

1 month ago - GlobeNewsWire

Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK's National Institute for Health and Care Excellence (NICE)

Final draft guidance based on cost effectiveness evaluation of sotrovimab Final draft guidance based on cost effectiveness evaluation of sotrovimab

1 month ago - GlobeNewsWire

This biotech stock could double from here: Goldman Sachs

Vir Biotechnology Inc (NASDAQ: VIR) jumped nearly 10% this morning after a Goldman Sachs analyst turned super bullish on the clinical-stage immunology company.

1 month ago - Invezz

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter a...

1 month ago - GlobeNewsWire

Vir Biotechnology, Inc. (VIR) Expected to Beat Earnings Estimates: Should You Buy?

Vir Biotechnology, Inc. (VIR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Vir Biotechnology Appoints Sung Lee as Chief Financial Officer

– Experienced biotech executive brings more than 20 years of financial leadership to Vir –

1 month ago - GlobeNewsWire

Vir Biotechnology Announces Amended Collaboration Agreement with GSK

– Vir to continue advancing next-generation COVID-19 solutions  independently or with other partners –

1 month ago - GlobeNewsWire

The 7 Most Undervalued Biotech Stocks to Buy in February 2023

You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edg...

1 month ago - InvestorPlace

7 Healthcare Stocks That Will Be Big Winners in 2023

Healthcare stocks performed well in 2022, driven by a number of factors. One of the main drivers was the ongoing COVID-19 pandemic, which continued to boost demand for healthcare products and services...

Other symbols: HRMYLLYMCKMRKNVOUNH
2 months ago - InvestorPlace

Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D.

– Dr. De Backer to assume CEO role on April 3, 2023 –

2 months ago - GlobeNewsWire

Vir Biotechnology, Inc. (VIR) Moves to Strong Buy: Rationale Behind the Upgrade

Vir Biotechnology, Inc. (VIR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?

Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference

– Critical Phase 2 readouts anticipated in 2023 for three advanced programs –  hepatitis B, hepatitis D and influenza –

3 months ago - GlobeNewsWire

3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023

Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.

Other symbols: GLPGPCRX
3 months ago - Zacks Investment Research

Should Value Investors Buy Vir Biotechnology (VIR) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

3 months ago - Zacks Investment Research

Vir Biotechnology: A 'Magic Formula' Top Performer

Joel Greenblatt (Trades, Portfolio), the manager of Gotham Capital, has what he calls a “Magic Formula” for investing. First detailed in "The Little Book That Beats the Market," this formula is based ...

3 months ago - GuruFocus

Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A

– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 – – Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 –

3 months ago - GlobeNewsWire

Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 71%: Here's is How to Trade

The consensus price target hints at a 70.9% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...

4 months ago - Zacks Investment Research

5 Winning Stocks Backed by the Overlooked Rising P/E Trick

Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).

Other symbols: AMCCURIHSDTLYV
4 months ago - Zacks Investment Research